Abstract | BACKGROUND: METHODS: This was a phase II trial using Simon's two-stage design. This study enrolled patients with endometrial cancer who had progressed after platinum-based chemotherapy. Sintilimab 200 mg was administered intravenously on day 1 every 3 weeks, and anlotinib 12 mg was administered on days 1-14 in a 21-day cycle. The primary endpoint was the objective response rate (ORR) using the immune-related Response Evaluation Criteria in Solid Tumors criteria. Immunohistochemistry and whole-exome sequencing were used as correlative investigations. RESULTS: Between November 2019 and September 2020, 23 eligible patients were enrolled. The ORR and disease control rates were 73.9% (95% CI, 51.6 to 89.8) and 91.3% (95% CI, 72.0 to 98.9), respectively, with 4 complete and 12 partial responses. With a median follow-up of 15.4 months (95% CI, 12.6 to 18.3), the median progression-free survival was not reached, and the probability of PFS >12 months was 57.1% (95% CI, 33.6 to 75.0). Exploratory analysis revealed that mutations in the homologous repair pathway showed a trend for higher ORR (100% vs 0%, p=0.07). Treatment-related grade 3/4 adverse events were observed in 50.0% of the patients. CONCLUSIONS: TRIAL REGISTRATION NUMBER: NCT04157491.
|
Authors | Wei Wei, Xiaohua Ban, Fan Yang, Jibin Li, Xiaqin Cheng, Rong Zhang, Xin Huang, Yongwen Huang, Qiaqia Li, Ya Qiu, Min Zheng, Xiaofeng Zhu, Jundong Li |
Journal | Journal for immunotherapy of cancer
(J Immunother Cancer)
Vol. 10
Issue 5
(05 2022)
ISSN: 2051-1426 [Electronic] England |
PMID | 35623659
(Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- Biomarkers
- Indoles
- Quinolines
- anlotinib
- sintilimab
|
Topics |
- Antibodies, Monoclonal, Humanized
- Biomarkers
- Endometrial Neoplasms
(drug therapy)
- Female
- Humans
- Indoles
- Quinolines
(pharmacology, therapeutic use)
|